Abstract
Angiogenesis inhibition with the anti-VEGF agent bevacizumab has been shown to enhance clinical benefits of cytotoxic chemotherapeutic drugs in various solid tumors, but has failed to mediate this effect in pancreatic ductal adenocarcinoma (PDAC). We have been interested in the therapeutic exploration of endothelial monocyte activating polypeptide II (EMAP II), and antiangiogenic, antiendothelial cytokine, in combination treatment of experimental PDAC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
